QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03552718|
Recruitment Status : Recruiting
First Posted : June 12, 2018
Last Update Posted : August 17, 2018
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Triple Negative Breast Cancer Head and Neck Squamous Cell Carcinoma Melanoma Non Small Cell Lung Cancer Pancreatic Cancer Liver Cancer Hormone Receptor Positive Tumor||Biological: YE-NEO-001||Phase 1|
This is a phase 1 trial to evaluate the safety, the RP2D, and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative therapy for their type of solid cancer (eg, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, melanoma) and would otherwise be entering a period of surveillance for recurrent disease.
The study will be conducted in two parts: part 1 will involve dose escalation, and part 2 will involve the expansion of the RP2D to further evaluate the safety of YE-NEO-001. In part 2 of the study, dose expansion will occur when the RP2D has been determined. An additional 4 subjects may be enrolled in part 2, for a total of up to 10 subjects at the RP2D.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.|
|Actual Study Start Date :||August 10, 2018|
|Estimated Primary Completion Date :||December 30, 2019|
|Estimated Study Completion Date :||December 30, 2020|
|Experimental: Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)||
Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
Other Name: YE-NEO-001 Injectable Suspension
- Incidence of treatment-emergent adverse events [ Time Frame: 19 months ]
- Recommended Phase 2 Dose [ Time Frame: 19 months ]
- Recurrence rate [ Time Frame: 19 months ]
- Disease-free survival (DFS) [ Time Frame: 24 months ]
- Overall survival (OS) [ Time Frame: 36 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03552718
|Contact: NantBio Clinical Review Team||800-988-6083||clinical.trials@NantKwest.com|
|United States, California|
|Chan Soon-Shiong Institute for Medicine||Recruiting|
|El Segundo, California, United States, 90245|